Halozyme earnings date
Halozyme (HALO) Q3 2026 Earnings Report
MX:HALO Q3 2026 EPS Results
- Actual EPS
- MXN 44.45
- Consensus EPS
- MXN 42.87
- Beat/Miss
- Beat by +MXN 1.58
- One Year Ago EPS
- MXN 31.99
MX:HALO Q3 2026 Revenue Results
- Actual Revenue
- MXN 9.17B
- Expected Revenue
- MXN 9.14B
- Beat/Miss
- Beat by +MXN 25.05M
- YoY Revenue Growth
- +39.15%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/05/2026
- Time
- After Close
- Conference Call
- Thursday, November 5, 2026
Halozyme's next earnings date is estimated for February 23, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive, supported by record revenue and royalty results, raised 2026 guidance, broad-based commercial product growth, expanding partner agreements, pipeline advancement and progress with Hypercon and Aerocon. The main negative items were higher operating expenses, adverse initial U.S. patent rulings, ongoing litigation and development and collaboration-revenue timing uncertainties, but these were outweighed by the reported operating momentum and growth opportunities.
Halozyme raised 2026 guidance to total revenue of $1.86 billion to $1.925 billion, representing growth of 33% to 38% over 2025; royalty revenue of $1.235 billion to $1.255 billion, representing growth of 42% to 45%; product sales of $525 million to $540 million; adjusted EBITDA of $1.24 billion to $1.29 billion, with adjusted EBITDA margin unchanged at approximately 67%; and non-GAAP diluted EPS of $8.75 to $9.05. The company expects 13 ENHANZE programs in clinical development by year-end 2026, Hypercon’s first clinical trial start in the first half of 2027, Aerocon new deal signings in 2027 and clinical entry in the second half of 2028, and up to 13 new products to launch between '29 and 2032, with development timelines of 4.5 to 5.5 years; it plans to provide 2027 guidance and an update on its long-range outlook when it reports fourth quarter results in February.
- Record Third-Quarter Revenue and ProfitabilityTotal revenue increased 39% year-over-year to $493 million, royalty revenue increased 44% to a record $341 million, adjusted EBITDA increased 35% to $336.2 million, and adjusted EBITDA margin was 68%. Net income increased 41% to $247 million, GAAP diluted EPS increased to $2.01 from $1.43, and non-GAAP diluted EPS increased to $2.39 from $1.72.
- Strong Royalty Portfolio GrowthDARZALEX royalty revenue increased 20% year-over-year to $153.5 million, VYVGART royalties increased 89% to $88.1 million, Phesgo royalty revenue increased 23% to $34.3 million, and other royalty revenue increased 92% to $65.1 million, driven by OCREVUS ZUNOVO, OPDIVO Qvantig, RYBREVANT FASPRO and TECENTRIQ HYBREZA.
- Raised Full-Year 2026 GuidanceThe company raised 2026 total revenue guidance to $1.86 billion to $1.925 billion, representing growth of 33% to 38% over 2025. Royalty revenue guidance increased to $1.235 billion to $1.255 billion, representing growth of 42% to 45%; product sales guidance increased to $525 million to $540 million; adjusted EBITDA guidance increased to $1.24 billion to $1.29 billion with an adjusted EBITDA margin of approximately 67%; and non-GAAP diluted EPS guidance increased to $8.75 to $9.05.
- Expanded ENHANZE Partner AgreementsThree current ENHANZE partners expanded their agreements and nominated four additional targets. Argenx added two exclusive targets, bringing its total to eight; Incyte added a target to evaluate subcutaneous axatilimab; and Johnson & Johnson added an oncology target. The company stated that these nominations diversify partner pipelines and add potential sources of milestone and royalty revenues.
- Expansion of the ENHANZE Clinical PipelineThree ENHANZE-enabled programs from Pfizer, Incyte and argenx advanced into Phase I development. With GSK planning to initiate a Phase Ib study of subcutaneous belantamab, Halozyme has 12 ENHANZE programs in clinical development and is on track to reach 13 by year-end 2026.
- Progress Across New ENHANZE Clinical ProgramsPfizer initiated a Phase I study of tilrekimig, Incyte initiated a Phase I study of a subcutaneous antibody targeting mutant calreticulin, and argenx is evaluating ARGX-119, a humanized agonist monoclonal antibody targeting MuSK. The company said multiple partners are moving programs from collaboration signing into the clinic within months.
- Strong OCREVUS ZUNOVO AdoptionApproximately 56,000 patients globally were receiving the 10-minute subcutaneous OCREVUS ZUNOVO formulation, an increase of about 12,000 patients since the first half of the year. Global conversion from OCREVUS IV exceeded 20%, and Roche reported that approximately 50% of OCREVUS ZUNOVO starts were patients naive to OCREVUS treatment.
- OPDIVO Qvantig Conversion Tracking Toward the High End of ExpectationsBristol-Myers Squibb reported that approximately 17% of OPDIVO IV business had converted to OPDIVO Qvantig, with uptake across multiple tumor types. Conversion is tracking toward the higher end of the expected range of 30% to 40% of the IV business.
- RYBREVANT FASPRO Growth OpportunityJohnson & Johnson reported 63.5% third-quarter growth for RYBREVANT plus LAZCLUZE, driven by share gains in first- and second-line lung cancer treatment, continued launch uptake across regions and rapid adoption of RYBREVANT FASPRO. J&J expects FDA approval of RYBREVANT FASPRO in advanced head and neck cancer by the end of 2026.
- DARZALEX Subcutaneous Continues to Gain ShareDARZALEX generated $4.2 billion in third-quarter sales, reflecting operational growth of 15.6%. Virtually all reported sales were for the DARZALEX subcutaneous version with ENHANZE, and growth was driven by continued share gains across all lines of therapy, including 10 points of share gain in the frontline setting, together with ongoing market expansion.
- VYVGART Hytrulo Delivered Robust GrowthArgenx reported total VYVGART sales of $1.7 billion, up 54% year-over-year and 13% sequentially. Growth continued in generalized myasthenia gravis and CIDP, supported by the VYVGART Hytrulo prefilled syringe. Approval for seronegative myasthenia gravis broadened the prescriber base, with approximately 10% of seronegative prescribers new to VYVGART.
- Additional VYVGART Expansion OpportunitiesArgenx is seeking an sBLA by year-end for immune-mediated necrotizing myositis, a population estimated by argenx at approximately 20,000 patients living with the disease in the United States. Potential approvals in ocular and pediatric myasthenia gravis are projected for 2027.
- Continued Phesgo ConversionGlobal Phesgo conversion from Perjeta reached 59%, up 5 percentage points since midyear. The company stated that continued conversion six years after launch reinforces the durability of Phesgo, with royalties projected into the 2030s.
- Patent and Litigation Progress in EuropeOn October 7, 2026, the specialized Dutch Patent Court of The Hague rejected Merck's invalidity challenges against Halozyme's EP622 patent and found Keytruda Qlex to be infringing. The court prohibited infringement in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands, following a December 2025 preliminary injunction in Germany. Halozyme stated that the affected European markets represent about 20% of total global royalties from the subcutaneous market.
- Hypercon and Aerocon Development ProgressHypercon and Aerocon have demonstrated stable biologic formulations at approximately 500 milligrams per milliliter, which the company described as 3 to 4 times what is commonly achieved. Hypercon has five collaboration and licensing agreements covering more than 20 potential targets or drugs. Halozyme is on track to complete clinical supply for two Hypercon partner products in the first quarter of 2027 to support Phase I starts in the first half of 2027, while Aerocon remains on track for new deal signings in 2027 and clinical entry in the second half of 2028.
- Potential Hypercon Royalty OpportunityHalozyme stated that its projection for a $1 billion Hypercon royalty opportunity assumes five to seven products in the clinic by before the mid-2030s. The majority of those products are already clinically derisked commercial products, with some earlier-stage products also expected to have potential to launch by that time.
- Patent Protection for Partner InnovationsCollaboration patents have been obtained by licensees for seven of the ten launch products, with collaboration patents pending for the others. Halozyme expects additional collaboration patents to be granted as partners generate new clinical-trial data.
- Strengthened Balance Sheet and Capital ReturnHalozyme completed a $1.5 billion convertible note offering on attractive terms. The company completed $400 million of share repurchases in 2026, ended the quarter with $1.08 billion in cash, cash equivalents and marketable securities, reported net leverage of 2.4x, and stated that it remains focused on addressing its 2027 and 2028 convertible notes at maturity.
- Strong Cash Generation and Disciplined Investment StrategyManagement said strong cash generation and financial flexibility provide capacity to invest in ENHANZE, Hypercon and Aerocon while maintaining a disciplined capital allocation framework. The company stated that it will evaluate selective strategic opportunities that complement its portfolio and meet criteria for strategic fit, durable value creation and attractive returns.
- Expected Future Product Launch WaveHalozyme stated that up to 13 new molecular entities could launch between 2029 and 2032 if they follow the company's usual development timeline of 4.5 to 5.5 years. The company also stated that the pipeline includes durable royalties, with many projected into the 2040s.
MX:HALO Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 23, 2027 | 2026 (Q4) | 47.73- | -4.46 | ― | ― |
| Nov 05, 2026 | 2026 (Q3) | 42.8744.45 | 31.99 | 38.95% (+12.46) | |
| Aug 06, 2026 | 2026 (Q2) | 33.2442.41 | 28.64 | 48.05% (+13.76) | |
| May 11, 2026 | 2026 (Q1) | 28.7429.76 | 20.65 | 44.14% (+9.11) | |
| Feb 17, 2026 | 2025 (Q4) | 40.88-4.46 | 23.44 | -119.05% (-27.90) | |
| Nov 03, 2025 | 2025 (Q3) | 30.3231.99 | 23.62 | 35.43% (+8.37) | |
| Aug 05, 2025 | 2025 (Q2) | 23.5828.64 | 16.93 | 69.23% (+11.72) | |
| May 06, 2025 | 2025 (Q1) | 17.6320.65 | 14.69 | 40.51% (+5.95) | |
| Feb 18, 2025 | 2024 (Q4) | 21.5423.44 | 15.25 | 53.66% (+8.18) | |
| Oct 31, 2024 | 2024 (Q3) | 18.4323.62 | 13.95 | 69.33% (+9.67) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


